Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignant glioma
• * Primary or recurrent glioblastoma multiforme (including gliosarcoma) following surgery and radiotherapy or prior conventional chemotherapy (e.g., carmustine or procarbazine, vincristine, and lomustine)
• * Recurrent or refractory anaplastic astrocytoma following any prior therapy (must be chemoresistant)
• * Recurrent or refractory ependymoma or primitive neuroectodermal tumor (PNET) following any prior therapy
• * Recurrent or refractory oligodendroglioma or oligoastrocytoma following any prior therapy (must be chemoresistant)
• Evaluable disease on gadolinium-enhanced MRI
• Ineligible for other high priority national or institutional study (e.g., protocol CAMP-004)
• PATIENT CHARACTERISTICS:
• Age:
• Any age
• Performance status:
• ECOG 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• Not specified
• Hepatic:
• Not specified
• Renal:
• Creatinine less than 1.5 times normal
• Cardiovascular:
• LVEF at least 45% by MUGA
• Pulmonary:
• DLCO at least 60% of predicted OR
• Approval by pulmonologist
• Other:
• Not pregnant or nursing
• Fertile patients must use effective contraception
• HIV negative
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• No other concurrent chemotherapy
• Endocrine therapy:
• No concurrent anticancer hormonal therapy
• No concurrent steroids as antiemetics
• Radiotherapy:
• See Disease Characteristics
• See Surgery
• Surgery:
• See Disease Characteristics
• For patients with glioblastoma multiforme, concurrent surgery and/or stereotactic radiosurgery to reduce tumor bulk allowed
• Other:
• No concurrent acetaminophen during chemotherapy